Cargando…
Mutant p53 as a guardian of the cancer cell
Forty years of research have established that the p53 tumor suppressor provides a major barrier to neoplastic transformation and tumor progression by its unique ability to act as an extremely sensitive collector of stress inputs, and to coordinate a complex framework of diverse effector pathways and...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6329812/ https://www.ncbi.nlm.nih.gov/pubmed/30538286 http://dx.doi.org/10.1038/s41418-018-0246-9 |
_version_ | 1783386874825408512 |
---|---|
author | Mantovani, Fiamma Collavin, Licio Del Sal, Giannino |
author_facet | Mantovani, Fiamma Collavin, Licio Del Sal, Giannino |
author_sort | Mantovani, Fiamma |
collection | PubMed |
description | Forty years of research have established that the p53 tumor suppressor provides a major barrier to neoplastic transformation and tumor progression by its unique ability to act as an extremely sensitive collector of stress inputs, and to coordinate a complex framework of diverse effector pathways and processes that protect cellular homeostasis and genome stability. Missense mutations in the TP53 gene are extremely widespread in human cancers and give rise to mutant p53 proteins that lose tumor suppressive activities, and some of which exert trans-dominant repression over the wild-type counterpart. Cancer cells acquire selective advantages by retaining mutant forms of the protein, which radically subvert the nature of the p53 pathway by promoting invasion, metastasis and chemoresistance. In this review, we consider available evidence suggesting that mutant p53 proteins can favor cancer cell survival and tumor progression by acting as homeostatic factors that sense and protect cancer cells from transformation-related stress stimuli, including DNA lesions, oxidative and proteotoxic stress, metabolic inbalance, interaction with the tumor microenvironment, and the immune system. These activities of mutant p53 may explain cancer cell addiction to this particular oncogene, and their study may disclose tumor vulnerabilities and synthetic lethalities that could be exploited for hitting tumors bearing missense TP53 mutations. |
format | Online Article Text |
id | pubmed-6329812 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-63298122019-01-17 Mutant p53 as a guardian of the cancer cell Mantovani, Fiamma Collavin, Licio Del Sal, Giannino Cell Death Differ Review Article Forty years of research have established that the p53 tumor suppressor provides a major barrier to neoplastic transformation and tumor progression by its unique ability to act as an extremely sensitive collector of stress inputs, and to coordinate a complex framework of diverse effector pathways and processes that protect cellular homeostasis and genome stability. Missense mutations in the TP53 gene are extremely widespread in human cancers and give rise to mutant p53 proteins that lose tumor suppressive activities, and some of which exert trans-dominant repression over the wild-type counterpart. Cancer cells acquire selective advantages by retaining mutant forms of the protein, which radically subvert the nature of the p53 pathway by promoting invasion, metastasis and chemoresistance. In this review, we consider available evidence suggesting that mutant p53 proteins can favor cancer cell survival and tumor progression by acting as homeostatic factors that sense and protect cancer cells from transformation-related stress stimuli, including DNA lesions, oxidative and proteotoxic stress, metabolic inbalance, interaction with the tumor microenvironment, and the immune system. These activities of mutant p53 may explain cancer cell addiction to this particular oncogene, and their study may disclose tumor vulnerabilities and synthetic lethalities that could be exploited for hitting tumors bearing missense TP53 mutations. Nature Publishing Group UK 2018-12-11 2019-02 /pmc/articles/PMC6329812/ /pubmed/30538286 http://dx.doi.org/10.1038/s41418-018-0246-9 Text en © The Author(s) 2018 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Review Article Mantovani, Fiamma Collavin, Licio Del Sal, Giannino Mutant p53 as a guardian of the cancer cell |
title | Mutant p53 as a guardian of the cancer cell |
title_full | Mutant p53 as a guardian of the cancer cell |
title_fullStr | Mutant p53 as a guardian of the cancer cell |
title_full_unstemmed | Mutant p53 as a guardian of the cancer cell |
title_short | Mutant p53 as a guardian of the cancer cell |
title_sort | mutant p53 as a guardian of the cancer cell |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6329812/ https://www.ncbi.nlm.nih.gov/pubmed/30538286 http://dx.doi.org/10.1038/s41418-018-0246-9 |
work_keys_str_mv | AT mantovanifiamma mutantp53asaguardianofthecancercell AT collavinlicio mutantp53asaguardianofthecancercell AT delsalgiannino mutantp53asaguardianofthecancercell |